Sofosbuvir/velpatasvir for the treatment of HCV: excellent results from a phase-3, open-label study in Russia and Sweden

References

• The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161–176.
   PubMed Web of Science ®Google Scholar
• Isakov V, Zhdanov K, Kersey K, et al. Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study. Antivir Ther (Lond). 2016;21:671–678.
   PubMed Web of Science ®Google Scholar
• AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available from: http://www.hcvguidelines.org.
   Google Scholar
• European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461–511.
   PubMed Web of Science ®Google Scholar
• Pyadushkina E. The burden of hepatitis C in Russia. Part 2. Presented at: The International Society for Pharmacokinetics and Outcomes Research (ISPOR) 19th Annual European Congress; 2016 Oct 29–Nov 2; Vienna, Austria.
   Google Scholar
• Kadmon Pharmaceuticals LLC. Ribasphere (ribavirin, USP) Tablets for oral use. US Prescribing Information. 2014; Available from: https://kadmon.com/files/ribasphere-tablets-pi.pdf.
   Google Scholar
• Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev. 2014;28:CS005441.
   Google Scholar
• Hoffmann-La Roche Inc. PEGASYS (peginterferon alfa-2a) injection, for subcutaneous use. U.S. Prescribing Information. 2015; Available from: https://www.gene.com/download/pdf/pegasys_prescribing.pdf.
   Google Scholar
• Larrey D, Ripault MP, Pageaux GP. Patient adherence issues in the treatment of hepatitis C. Patient Prefer Adher. 2014;8:763–773.
   PubMed Web of Science ®Google Scholar
• Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutierrez T, et al. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol. 2015;14:46–57.
   PubMed Web of Science ®Google Scholar
• Isakov V, Nikitin I, Chulanov V, et al. Boceprevir plus peginterferon/ribavirin for treatment of chronic hepatitis C in Russia. World J Hepatol. 2016;8:331–339.
   PubMed Web of Science ®Google Scholar
• Ocheret D, Bikmukhametov D, Sultangaziev A, et al. Current situation regarding access to hepatitis C treatment in Eastern Europe and Central Asia. 2013; Available from: http://www.harm-reduction.org/sites/default/files/pdf/hep_c_policy_brief_update_en_edited_3.pdf
   Google Scholar
• Krasnova L. Burden of hepatitis C in Russia. Presented at: The International Society for Pharmacokinetics and Outcomes Research (ISPOR) 19th Annual European Congress; 2016 Oct 29–Nov 2; Vienna, Austria.
   Google Scholar
• Leblebicioglu H, Arends JE, Ozaras R, et al. Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Res. 2018;150:9–14.
   PubMed Web of Science ®Google Scholar
• Hatzakis A, Chulanov V, Gadano AC, et al. The present and future disease burden of hepatitis C virus (HCV) infections with today’s treatment paradigm - volume 2. J Viral Hepat. 2015;22(Suppl. 1): 26–45.
   PubMedGoogle Scholar
• Hill AM, Nath S, Simmons B. The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries. J Virus Erad. 2017;3:117–123.
   PubMed Web of Science ®Google Scholar
• Lagging M, Wejstal R, Duberg AS, et al. Treatment of hepatitis C virus infection: updated Swedish consensus guidelines 2017. Infect Dis (Lond). 2018;50:569–583.
   PubMed Web of Science ®Google Scholar
• Epclusa: EPAR – product information; [cited 18 Oct 2017]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004210/human_med_001997.jsp&mid=WC0b01ac058001d124.
   Google Scholar
• Epclusa: prescribing information; [cited 18 Oct 2017]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf.
   Google Scholar
• Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–2628.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–2607.
   PubMed Web of Science ®Google Scholar
• Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–2617.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016;65:33–39.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: Results from ASTRAL-2 and -3 clinical trials. Clin Infect Dis. 2016;63:1042–1048.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Charlton M, et al. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. Lancet Gastroenterol Hepatol. 2016;1:122–132.
   PubMed Web of Science ®Google Scholar
• Mukomolov S, Trifonova G, Levakova I, et al. Hepatitis C in the Russian Federation: challenges and future directions. Hepat Med. 2016;8:51–60.
   PubMed Web of Science ®Google Scholar
• Andrey Rylkov Foundation for Health and Social Justice. Hepatitis C in Russia: an epidemic of negligence. 2013. Available from: http://en.rylkov-fond.org/blog/hcv/hcvrus/.
   Google Scholar
• Duberg AS, Blach S, Falconer K, et al. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies. Scand J Gastroenterol. 2015;50:233–244.
   PubMed Web of Science ®Google Scholar
• Ahmed H, Abushouk AI, Attia A, et al. Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis. J Infect Public Health. 2018;11:156–164.
   PubMed Web of Science ®Google Scholar
• Berden FA, Aaldering BR, Groenewoud H, et al. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2017;15:349–359.
   PubMed Web of Science ®Google Scholar